Cancer Screening Recommendations for a 74-Year-Old Female
For a 74-year-old woman in good health, continue biennial screening mammography for breast cancer and initiate colorectal cancer screening if not already up to date; cervical cancer screening should be discontinued if prior screening has been adequate. 1, 2
Breast Cancer Screening
Continue biennial mammography screening. At age 74, this patient falls within the evidence-based screening window where benefits clearly outweigh harms 2, 1. The most recent USPSTF 2024 guidelines recommend biennial screening mammography through age 74 with moderate certainty of net benefit 2. The 2026 American College of Physicians guidance similarly supports biennial mammography for women aged 50-74 years 1.
Key Considerations for Breast Screening:
- Screening interval: Biennial (every 2 years) provides the best balance of benefits and harms for this age group 3
- Modality: Digital mammography or digital breast tomosynthesis (DBT) are both appropriate 4
- When to stop: The decision to continue beyond age 75 should be based on overall health status and life expectancy rather than age alone 4, 5
Important nuance: While the ACR 2024 guidelines note that observational studies show women ≥75 years may continue to benefit from screening, randomized trials did not include women over 74 4, 5. The mortality reduction from screening requires years to be fully realized, so screening should continue only if life expectancy exceeds 7-10 years 6, 7.
Stopping Criteria:
- Life expectancy less than 7-10 years 6, 7
- Significant comorbidities (advanced heart failure, COPD, dementia, end-stage organ disease) 6
- Patient unwilling to undergo follow-up testing or biopsy if abnormality detected 4
Clinical breast examination is NOT recommended for screening at any age 6
Colorectal Cancer Screening
Ensure colorectal cancer screening is up to date through age 75. While the evidence provided focuses primarily on breast screening, colorectal cancer screening remains a priority through age 75 for average-risk individuals 8.
Recommended Options (choose one):
- Annual fecal immunochemical test (FIT) or high-sensitivity guaiac-based fecal occult blood test
- Colonoscopy every 10 years
- Flexible sigmoidoscopy every 5 years
- Stool-based molecular tests (mt-sDNA or mt-sRNA) every 3 years 9
Stopping age: Continue through age 75 for those with life expectancy >10 years 9
Cervical Cancer Screening
Discontinue cervical cancer screening if the patient has had consistently normal prior screening results. Women who have been adequately screened can stop at age 65-70 8. At age 74 with prior normal screening, continued Pap testing provides minimal additional benefit (only 0.06% reduction in mortality at age 74) 8.
Exception:
Continue screening only if she has never been adequately screened previously 8
Other Cancer Screenings
Lung cancer screening: Consider low-dose CT screening if she has a ≥20 pack-year smoking history and currently smokes or quit within the past 15 years (though this evidence was not provided in detail)
Prostate cancer screening: Not applicable for female patients
Critical Implementation Points
Shared Decision-Making Elements:
When discussing continuation of breast screening beyond this year:
- Assess overall health status and functional capacity
- Estimate life expectancy based on comorbidities
- Discuss that screening benefits take 7-10 years to fully materialize 6, 7
- Review patient values regarding early detection versus potential harms (false positives, unnecessary biopsies, overdiagnosis)
Common Pitfalls to Avoid:
- Don't use age 75 as an absolute cutoff - base decisions on health status and life expectancy 4, 6, 5
- Don't recommend supplemental screening (ultrasound, MRI) for average-risk women, even with dense breasts, outside of high-risk populations 6, 2, 1
- Don't continue cervical cancer screening in adequately screened older women - the yield is extremely low 8
Practical Algorithm for Next Year (Age 75):
IF good health + life expectancy >7-10 years + willing to undergo follow-up:
IF significant comorbidities OR life expectancy <7-10 years OR patient preference against screening:
For colorectal screening at age 75: Similar approach - continue only if life expectancy >10 years 9